With intensified domestic competition in China’s medical device sector, the trillion-dollar ASEAN healthcare market has become a core overseas expansion destination for Chinese medical device manufacturers. Malaysia’s Medical Device Authority (MDA) has formally launched permanent two-way mutual recognition schemes between Singapore-Malaysia and Malaysia-Thailand. Combined with the GHTF multi-country mutual recognition framework, manufacturers can register products once to rapidly access the three key markets of Singapore, Malaysia and Thailand, cutting approval timelines in half and slashing compliance costs drastically.
Pilot phase: 1 September 2025 – 28 February 2026 (6-month pilot successfully completed)
Official rollout: Permanent implementation starting 1 March 2026
Official guideline: MDA/GD/0070 issued by MDA, governing full standardized verification procedures
Partner authorities: Malaysia Medical Device Authority (MDA) ↔ Singapore Health Sciences Authority (HSA)
Core rules: Two-way mutual recognition. Class B/C/D medium-to-high risk devices qualify for simplified verification routes. Both sides mutually recognize audit, testing and clinical data, eliminating duplicate trials and assessments.Pilot phase: 1 February 2026 – 30 April 2026
Official rollout: Permanent implementation starting 1 May 2026
Partner authorities: Malaysia MDA ↔ Thailand Food and Drug Administration (TFDA)
Covered products: Class B/C/D medium-to-high risk medical devices. Two-way simplified registration procedures greatly reduce redundant review workload.Official rollout: Permanent implementation starting 1 May 2026
Partner authorities: Malaysia MDA ↔ Thailand Food and Drug Administration (TFDA)
Covered products: Class B/C/D medium-to-high risk medical devices. Two-way simplified registration procedures greatly reduce redundant review workload.
Halved approval timelines：Standard full review takes 60 working days, while the mutual recognition verification route only requires 30 working days, significantly shortening time-to-market and enabling faster market penetration.
Sharply reduced compliance expenses：Duplicate technical reviews, product testing and clinical validation are waived. Full exemptions apply to testing fees, expert assessment fees and registration service charges, drastically cutting overseas compliance investment.
No repeated trials, global data reuse：If your product is already registered in Singapore or Thailand with identical specifications, design and intended use, you may directly adopt Malaysia MDA’s verification pathway without redeveloping full technical documentation or repeating clinical trials.
Two-way interoperability: One registration covers two markets
Product scope: Only applicable to Class B/C/D medium-to-high risk medical devices; Class A low-risk devices are excluded temporarily.
Product consistency: The submitted product must match the version registered in the mutual recognition country, with no changes to design, specifications, indications or raw materials.
Submission channel: All applications filed online via Malaysia’s official electronic regulatory system MeDC@St.
Compliance verification: Document validation must be completed by a Conformity Assessment Body (CAB) accredited by MDA.
Prerequisite: Valid registration certificate issued by Singapore HSA or Thailand TFDA.
Route selection: MDA exclusive Verification Route.
Process: Online submission of full technical dossier → CAB document verification → MDA compliance inspection → Registration completed within 30 working days.
Prerequisite: Valid MDA Malaysia medical device registration certificate.
Route: Local simplified mutual recognition channel.
Advantages: Waived in-depth local technical reviews, shorter approval lead times and reduced dossier preparation workload.
Beyond ASEAN regional mutual recognition, Malaysia MDA maintains alignment with major global regulatory systems, serving as a pivotal hub for Chinese medical device manufacturers to enter worldwide markets:
Mutual recognition among GHTF founding member jurisdictions
Full EU CE MDD/IVDD/AIMDD certification with automatic entry into the Eudamed database
Recognition of US FDA 510(k)/PMA, Japan PMDA and UK UKNI certificationsEnterprises can leverage Malaysia as a springboard to expand simultaneously across Southeast Asia, Europe, the Americas, Japan and South Korea, reusing one compliance system across multiple regions.As the largest medical device market in Latin America with the most mature regulatory framework, Brazil is a core strategic territory for Chinese medical device companies expanding into South America.
To celebrate Wiselink’s 6th Anniversary, we are launching a limited-time special offer:
From 18 June to 18 July, consultation service fees for all risk classes of medical devices for the Brazil market will be offered at a uniform 20% discount!
New and existing clients are welcome to reach out for consultation.
